Large Molecule Patents
Neulasta is a drug owned by Amgen Inc.. It is protect by 1 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9856287 | AMGEN INC. | Refolding proteins using a chemically controlled redox state |
Jun, 2030
(5 years from now) | Active |
Neulasta's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
About Neulasta
Active Ingredients:
Neulasta contains Pegfilgrastim as an active ingredient
Approval Date:
Neulasta was first approved for market use on 31 Jan, 2002.
Dosage:
Neulasta is available in 1 strengths and the following dosage forms are - Injection form for Subcutaneous use, Injection form for Subcutaneous use.
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 6MG/0.6ML | Injection | Rx | Subcutaneous |
| 6MG/0.6ML | Injection | Rx | Subcutaneous |
| 6MG/0.6ML | Injection | Rx | Subcutaneous |
| 6MG/0.6ML | Injection | Rx | Subcutaneous |